China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced that it has received another market approval from the National Medical Products Administration (NMPA) for its triptorelin microspheres, now indicated for the treatment of endometriosis.
Triptorelin microspheres are an in-house developed long-acting formulation administered via monthly intramuscular injection as a gonadotropin-releasing hormone agonist. The product was initially approved for marketing in China in May of last year for the treatment of prostate cancer requiring androgen deprivation therapy. Compared to standard injectable triptorelin, the microsphere formulation offers a longer onset time and fewer administration requirements, which can alleviate patient discomfort and reduce the medication burden, ultimately enhancing drug tolerance and accessibility. -Fineline Info & Tech
